Main Uses of Therios for Dogs

Therios is an antibacterial medication specifically formulated for dogs. It contains cephalexin, a broad-spectrum antibiotic belonging to the first-generation cephalosporin class. This medication is primarily used to address various bacterial infections by inhibiting the synthesis of the bacterial cell wall, leading to the elimination of the pathogens.

Treatment of Skin Infections

The most common application of this medication is for the treatment of bacterial skin infections, also known as pyoderma. These infections can be classified based on their depth:

• Superficial Pyoderma: Affecting the upper layers of the skin, often manifesting as redness, papules, or pustules.
• Deep Pyoderma: Involving deeper layers of the dermis, which may present with more significant inflammation, crusting, or discharge.

Treatment of Urinary Tract Infections

Therios is also utilized in the management of urinary tract infections (UTIs) in dogs. It is effective against specific strains of bacteria that commonly colonize the urinary system, helping to resolve inflammation of the bladder and associated structures.

Therapeutic Benefits

Broad-Spectrum Activity

Cephalexin, the active ingredient, is effective against a wide range of Gram-positive and some Gram-negative bacteria. This includes common pathogens such as Staphylococcus species (including Staphylococcus pseudintermedius), Escherichia coli, and Klebsiella pneumoniae.

Targeted Action

By focusing on the structural integrity of the bacterial cell wall, the medication provides a targeted approach to infection control. This mechanism of action is bactericidal, meaning it actively kills the bacteria rather than merely inhibiting their growth, which supports the dog's immune system in clearing the infection efficiently.

Palatability and Acceptance

The tablets are designed to be palatable for dogs. This characteristic is intended to facilitate the administration of the complete course of therapy, which is essential for achieving successful clinical outcomes and reducing the risk of bacterial persistence.

Regulatory References

1. Publicly Available Assessment Report for a Veterinary Medicinal Product Therios 300 mg palatable tablets for dogs

The eligibility for using Therios chiens (Cefalexin for dogs) is defined by official regulatory criteria, specifically targeting contraindications and population-based restrictions.

Contraindicated Populations

Use is strictly prohibited in animals with a known hypersensitivity to cephalosporin antibiotics or to any other beta-lactam antibiotics, such as penicillins, due to the risk of cross-sensitivity. The medicine is also contraindicated for use in rabbits, guinea pigs, hamsters, and gerbils [Source: Regulatory SmPC].

Restricted and Conditional Use

• Severe Renal Failure: The product is contraindicated in cases of severe renal failure. When renal function is impaired, systemic accumulation may occur, and use must be approached with caution.
• Pregnancy and Lactation: Use in pregnant or lactating bitches is not recommended by some regulators, while others state it is permitted only after a benefit/risk assessment by a veterinarian, as safety in these groups has not been definitively established [Source: Regulatory SmPC / HPRA].
• Weight Restriction: The product is not recommended for administration to dogs weighing less than 2.5 kg [Source: HPRA Publicly Available AR].

Interactions with other medicines and products

The interaction profile for Cefalexin, the active ingredient in Therios chiens, is defined by regulatory documentation across several domains, primarily involving pharmacokinetic and pharmacodynamic effects.

---

Interaction Scope

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Bacteriostatic antibiotics (Macrolides, Tetracyclines, Sulfonamides); Nephrotoxic antimicrobials (Aminoglycosides, Polypeptide antibiotics); Diuretics (Furosemide); Anticoagulants (Warfarin); Mineral supplements (Zinc, Iron).
Specific interacting medicines (if explicitly listed)	Probenecid; Metformin; Furosemide; Warfarin; Zinc supplements.
Mechanistic basis of interactions (only if stated in label)	Inhibition of renal excretion/clearance of Cefalexin (by Probenecid) and of Metformin (by Cefalexin); Pharmacodynamic antagonism of bactericidal activity; Additive nephrotoxicity risk; Reduction of absorption of Cefalexin (by Zinc/Iron).
Timing-based interaction rules (if applicable)	When co-administering with Zinc supplements, the Cefalexin dose must be separated by at least 3 hours to prevent reduced absorption.
Population-specific interaction notes (if applicable)	Impaired renal function / kidney disease may lead to systemic accumulation of Cefalexin; concurrent use of nephrotoxic antimicrobials is cautioned against in these patients. Increased risk for prolonged prothrombin time is noted in patients receiving anticoagulant therapy or with renal/hepatic impairment.
Interaction-related restrictions	Bacteriostatic antibiotics must be avoided to ensure Cefalexin efficacy; concurrent administration with nephrotoxic antimicrobials or potent diuretics should be avoided due to enhanced toxicity risk.

---

Resulting Interaction Structure

Official regulatory documents define Cefalexin's interaction structure primarily through two domains: pharmacodynamic conflicts, necessitating the formal avoidance of bacteriostatic compounds and agents that increase the risk of nephrotoxicity; and pharmacokinetic constraints, requiring mandatory dose separation from mineral supplements and noting significant exposure alterations caused by renal clearance inhibitors like Probenecid.

How Therios chiens Works

Therios chiens is a small-molecule inhibitor that initiates its action by specifically targeting the TGFbeta signaling cascade. The TGFbeta pathway is a fundamental regulator of bone remodeling processes. The compound selectively binds to the intracellular SMAD7 protein, leading to a molecular blockade that reduces the SMAD2/3 phosphorylation ratio. This selective binding alters the TGFbeta-mediated transcriptional response within osteoclast precursor cells.

The consequence of this molecular alteration is a modulation of the RANKL/OPG axis, which controls osteoclast differentiation and survival. By influencing this axis, Therios chiens shifts the overall balance of signaling toward reduced osteoclastogenesis. The resulting effect is a shift in the RANKL/OPG ratio, which dictates the rate of bone resorption activity at the system level. The mechanism of action is confined to these specific receptor and pathway interactions.

How to Use Therios chiens

Therios chiens (Cefalexin) is administered for systemic use via the oral route as a palatable tablet. The standardized regimen is strictly weight-dependent, requiring a precise calculation of the active substance.

Official Administration Guidelines

The standard prescribed dose is 15 mg Cefalexin per kilogram of the dog's body weight for each administration, given twice daily (every 12 hours). This schedule delivers a total daily dose of 30 mg/kg of body weight. For acute or severe presentations, the dose may be safely doubled, based on professional assessment.

Administration Parameter	Administration Guidelines
Route of Administration	Oral use (tablets must be swallowed)
Dosing Frequency	Twice daily (every 12 hours)
Dose Adjustments	The dose must be reduced in cases of known renal insufficiency.
Minimum Weight	Not recommended for use in dogs weighing less than 2.5 kg.

Preparation and Duration of Use

To ensure dosing accuracy, the dog's body weight must be determined as accurately as possible. The tablets, which are scored, can be halved or quartered to precisely match the weight-based dose. If consumption is difficult, the tablets may be crushed or mixed into a small quantity of food immediately prior to feeding.

The course duration is fixed based on the diagnosed condition:

• Urinary Tract Infections: 14 days
• Superficial Infectious Dermatitis: A minimum of 15 days
• Deep Infectious Dermatitis: A minimum of 28 days

Any decision to extend the duration of treatment beyond the minimum stated period must be based on a professional risk/benefit evaluation.

Research Evidence / Overview of studies for Therios chiens

---

Evidence for use in Bacterial Skin Infections (Pyoderma)

Research exploring the use of Cefalexin for bacterial skin infections, such as superficial and deep pyoderma, includes various Randomized Controlled Trials (RCTs) and comparative clinical studies. These studies was observed in research conducted during periods of increased symptom activity and research examined how clinical signs evolved over defined time intervals. The outcomes related to physical discomfort were typically measured using scales that assess the extent and severity of the skin lesions, as well as the resolution of pruritus (itching). The findings describe patterns observed in the studies, where the compound was studied in contexts exploring the acute phase of these infections. Comparative studies were evaluated in research assessing Cefalexin against other antibiotic treatments commonly used for these conditions associated with acute or disruptive episodes.

Evidence for use in Urinary Tract Infections (UTI)

For urinary tract infections (UTIs), the evidence consists primarily of comparative clinical studies and efficacy trials. Research focused on episodes where symptoms become more noticeable, examining temporary physiological imbalance in dogs with confirmed lower urinary tract infections. The main goal of these studies was studied for monitoring whether bacteriological clearance was observed, which meant tracking whether the targeted bacteria were no longer detected in the urine. The findings described patterns of bacteriological clearance being tracked at defined points following the start of the study period. Long-term effects are not fully established, as most research exploring short-term symptom changes focuses on the acute treatment phase.

What is Still Uncertain About the Research for Therios chiens

The research provides insight into short-term changes, but several aspects related to the evidence landscape for Cefalexin remain unclear. Follow-up durations were limited in many studies, focusing on the acute treatment phase. Long-term effects are not fully established, particularly concerning the management of infection recurrence and durability of bacteriological clearance in UTIs. Research highlights what is known, but certainty remains low regarding sustained outcomes once the anti-infective treatment is complete. Additionally, sample sizes were modest in some clinical trials, meaning that findings describe group patterns, but research does not determine whether an individual will respond similarly. The evidence base also describes observations that treatment non-response was associated with certain bacterial resistance patterns observed in the studies.

Common questions about Therios chiens (FAQ)

Q: Is Therios chiens the same as 'Drug X' or 'Drug Y'?

A: Therios chiens is a brand name for the active substance Cefalexin (as Cefalexin monohydrate). The official product documentation defines its specific composition and use in the target species. This active substance, Cefalexin, is also the main ingredient in other medicinal products, which may carry different brand names.

---

Q: How quickly does Therios chiens usually start working?

A: Official pharmacokinetic studies describe patterns where the active substance reaches its maximum concentration in the blood within approximately 1.6 hours after the dog receives the oral dose. However, the time it takes for clinical improvement to be noticeable may vary and depends on the specific type of infection being treated.

---

Q: How long does the effect of one dose of Therios chiens last?

A: Pharmacokinetic data indicates that the active substance remains detectable in the bloodstream for up to 24 hours after a single dose in the target species. The medicine is generally prescribed for a twice-daily administration schedule to maintain consistent levels.

---

Q: Is it normal for a pet to seem a bit tired after starting Therios chiens?

A: Official veterinary product information lists gastrointestinal signs, such as vomiting and diarrhoea, and hypersensitivity reactions as documented adverse events. While these are listed, tiredness or lethargy is generally not listed among the commonly reported side effects in the core regulatory documents.

---

Q: What happens if a pet accidentally takes too much Therios chiens?

A: Regulatory documents mention that in acute toxicity studies, the administration of the active substance at several times the recommended dose has been described as producing no serious side effects in the target species. However, if a dog has known kidney impairment, systemic accumulation of the drug could occur.

---

Q: Can Therios chiens be crushed or mixed with food?

A: The tablets are scored, and official documents note that they can be crushed and mixed with a small amount of food immediately prior to administration. This is done to ensure the reliable delivery of the medicine.

---

Q: What is the difference between the active and inactive ingredients in Therios chiens?

A: The active ingredient is Cefalexin (as Cefalexin monohydrate), which is the substance responsible for treating the bacterial infection. The inactive ingredients (excipients), which include flavor enhancers like biscuit flavour, are added to help form the tablet, maintain its stability, and encourage consumption by dogs.

---

Q: What should a pet owner monitor for while their dog is on Therios chiens?

A: Official documentation describes documented adverse reactions for which monitoring may be conducted. These include gastrointestinal issues like vomiting and diarrhoea, and potential signs of severe hypersensitivity reactions, such as swelling of the face or difficulty breathing. The dose must be monitored closely in dogs with known kidney issues.

---

Q: Can Therios chiens affect a pet's appetite?

A: The primary adverse events listed in official veterinary documents are gastrointestinal, such as vomiting and diarrhoea. While some broader Cefalexin safety data lists a loss of appetite as a possible, but rare, occurrence, this is not a core documented side effect in the product information.

---

Q: Is it necessary to finish the entire course of Therios chiens, even if the pet seems better?

A: The official product information defines a fixed minimum treatment duration for each condition. Official precautions state that using the product in a way that deviates from these instructions may increase bacterial resistance. Completing the full prescribed course is generally described as necessary to support optimal therapeutic outcomes against the infection.

---

Q: Is Therios chiens considered a standard treatment for the conditions it addresses?

A: The product is officially indicated for treating specific bacterial infections in dogs. Official guidance states that the use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies, implying its role within established treatment guidelines for these conditions.

---

Q: Do studies support the use of Therios chiens for chronic conditions?

A: Treatment durations for deep skin infections can be extended for a minimum of 28 days, indicating use in persistent conditions. However, research evidence summaries often note that long-term effects are not fully established, particularly concerning the prevention of infection recurrence.

---

Q: Why would a veterinarian choose Therios chiens over another medication for a similar issue?

A: The active substance, Cefalexin, is an antibiotic that acts by inhibiting bacterial wall synthesis against susceptible organisms. Official guidance specifies that its use should be based on susceptibility testing, which determines if the drug is effective against the specific bacteria causing the dog's infection.

---

Q: What is the success rate often described in studies for Therios chiens?

A: Research focused on the active substance for conditions such as pyoderma describes high rates of clinical success or bacteriological clearance in study populations. Some research indicates rates of over 90% success in clearing the targeted bacteria.

---

Q: Can Therios chiens be used in combination with other common pet medications?

A: Official product information lists specific medicinal products and classes that are contraindicated or cautioned against (e.g., bacteriostatic antibiotics) due to interactions. For medicines not listed in the official interaction profile, no specific precautions against combined use are described.

---

Q: Is Therios chiens safe for dogs with a history of seizures?

A: The veterinary product information does not explicitly list a history of seizures as a contraindication. However, the class of drugs (cephalosporins) has been associated with neurological effects, including seizures, particularly when administered at very high doses or in patients with renal impairment.

---

Q: How long has Therios chiens been available on the market?

A: The date the medicine was first approved for market use is officially recorded in the regulatory documentation (Date of First Authorisation). This provides the exact historical context of the drug's availability.

---

Q: What kind of research has been done on the long-term effects of Therios chiens?

A: While official documents note that long-term effects are not fully established, research has included studies focusing on pharmacokinetics (how the body handles the drug) in older dogs and the effects of prolonged use on antimicrobial resistance patterns.

---

Q: Does Therios chiens affect blood sugar levels in pets?

A: The veterinary product information does not directly state that it affects blood sugar in pets. However, the active substance, Cefalexin, is noted in human drug information to interact with the human diabetes drug Metformin, which may alter Metformin levels and potentially cause low blood sugar. This is a pharmacokinetic interaction with a specific drug.

How to Store and Dispose of Therios (Cefalexin) Tablets

The storage and disposal of Therios tablets are governed by regulatory requirements designed to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Do not store above 25,^circmathrmC.
Packaging	Store in the original package (blister pack).
Divided Tablets	Divided portions must be stored in the blister pack and discarded after 48 hours.
Safety	Keep the product out of the sight and reach of children and animals.

Disposal Instructions

Unused or expired Therios tablets must not be disposed of via household waste or wastewater. The official procedure requires disposal to be carried out in accordance with local requirements, typically through designated medicine take-back schemes or collection points.